ELREXFIO elranatamab

Drug Class

Bispecific BCMA-directed CD3 T-cell engager

Mechanism

Binds BCMA on myeloma cells and CD3 on T-cells, triggering T-cell activation and cytolysis of BCMA-expressing cells.

Approved Indication

Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

What This Means For Patients

ELREXFIO is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2023) — Sources
• EMA — Approved (2023) — Sources

Pivotal Clinical Evidence

• MagnetisMM-3 — Lesokhin et al., Nat Med 2023 (NCT04649359) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio